Overview
NICE is unable to make a recommendation on fosdenopterin (Nulibry) for treating molybdenum cofactor deficiency type A in people of all ages. This is because Sentynl Therapeutics has withdrawn from the appraisal.
Last reviewed: 25 June 2025
Next review: We will review this decision if the company decides to make a submission.